866-997-4948(US-Canada Toll Free)

AIDS - Related Kaposi\'s Sarcoma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 34 Pages


Global Markets Directs, \'AIDS Related Kaposi\'s Sarcoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for AIDS Related Kaposi\'s Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS Related Kaposi\'s Sarcoma. 

AIDS Related Kaposi\'s Sarcoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for AIDS Related Kaposi\'s Sarcoma.
  • A review of the AIDS Related Kaposi\'s Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the AIDS Related Kaposi\'s Sarcoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for AIDS Related Kaposi\'s Sarcoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding AIDS Related Kaposi\'s Sarcoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
AIDS - Related Kaposi\'s Sarcoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for AIDS - Related Kaposi\'s Sarcoma 7
AIDS - Related Kaposi\'s Sarcoma Therapeutics under Development by Companies 9
AIDS - Related Kaposi\'s Sarcoma Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
AIDS - Related Kaposi\'s Sarcoma Therapeutics - Products under Development by Companies 14
AIDS - Related Kaposi\'s Sarcoma Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in AIDS - Related Kaposi\'s Sarcoma Therapeutics Development 16
Aphios Corporation 16
Merck KGaA 17
AIDS - Related Kaposi\'s Sarcoma - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
paclitaxel - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
cilengitide - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
bortezomib - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
halofuginone hydrobromide - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AIDS - Related Kaposi\'s Sarcoma Therapeutics - Drug Profile Updates 29
AIDS - Related Kaposi\'s Sarcoma Therapeutics - Discontinued Products 30
AIDS - Related Kaposi\'s Sarcoma Therapeutics - Dormant Products 31
AIDS - Related Kaposi\'s Sarcoma - Product Development Milestones 32
Featured News & Press Releases 32
Aug 05, 1997: Taxol Approved for Kaposi\'s Sarcoma 32

Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Table


Number of Products Under Development for AIDS - Related Kaposi\'s Sarcoma, H1 2013 7
Products under Development for AIDS - Related Kaposi\'s Sarcoma - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Aphios Corporation, H1 2013 16
Merck KGaA, H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 22
AIDS - Related Kaposi\'s Sarcoma Therapeutics - Drug Profile Updates 29
AIDS - Related Kaposi\'s Sarcoma Therapeutics - Discontinued Products 30
AIDS - Related Kaposi\'s Sarcoma Therapeutics - Dormant Products 31

List of Chart


Number of Products under Development for AIDS - Related Kaposi\'s Sarcoma, H1 2013 7
Products under Development for AIDS - Related Kaposi\'s Sarcoma - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 18
Assessment by Route of Administration, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Molecule Type, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *